GeneDx Holdings Corp. reported strong first-quarter results, achieving $87.1 million in total revenue, driven by a 62% year-over-year growth in exome and genome testing revenues, which reached $71.4 million. This growth reflects a 24% increase in test volume, with exome and genome tests now comprising 40% of all tests performed. The company also marked its third consecutive quarter of profitability, posting an adjusted net income of $7.7 million and raising its full-year revenue guidance to between $360 million and $375 million.
The results underscore GeneDx’s robust market position and strategic focus on genomic testing, particularly in the NICU segment, where the launch of ultra-rapid genome sequencing aims to enhance patient outcomes. The anticipated acquisition of Fabric Genomics is expected to further bolster profitability by introducing high-margin, recurring revenue streams and expanding the company’s international reach.
For market professionals, GeneDx’s performance highlights a significant opportunity in the genomic testing space, particularly as reimbursement trends improve and the company continues to innovate and expand its service offerings. The combination of strong revenue growth and strategic acquisitions positions GeneDx favorably for sustained market leadership.
Source: fool.com